HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho

Lexicon

PMDA-WEST:
医薬品医療機器総合機構関西支部

The Column

3 Reasons Why KOL Management Is No Longer Enough

Archives

Takeda Aims for Consecutive Sales Growth through FY2022(Oct.31)
Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan(Oct.31)
Eisai Flounders in Japan, US Markets, Half-Year Profits Dive 60%(Oct.31)
Cabinet OKs Appointment of Keio Prof as Japan NIH Head(Oct.31)
Takeda Reports 2.8% Rise in First-Half Sales(Oct.31)

Most Read

1.
Health Ministry...
2.
MHLW Orders Rev...
3.
MHLW Orders Rev...
4.
Janssen Ordered...
5.
Takeda Gains Wo...

News Calendar